Welcome to our dedicated page for McKesson news (Ticker: MCK), a resource for investors and traders seeking the latest updates and insights on McKesson stock.
McKesson Corporation (NYSE: MCK) is a diversified healthcare services and pharmaceutical distribution company that regularly issues news and updates relevant to investors, healthcare partners, and other stakeholders. The company describes itself as dedicated to advancing health outcomes for patients everywhere, partnering with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services that support access to quality care.
The McKesson news feed typically features announcements about quarterly and annual financial results, earnings release dates, and related investor webcasts. These updates often include information about fiscal guidance, long-term financial targets, and commentary on strategic priorities and business outlook shared during events such as Investor Day.
In addition to earnings and guidance, McKesson’s news includes Board actions such as dividend declarations, reflecting decisions on returning capital to shareholders. The company also issues releases on organizational and segment reporting changes, including the introduction of its North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions segments, along with portfolio developments like planned separations or divestitures.
McKesson may also appear in third-party announcements highlighting distribution agreements and collaborations that illustrate its role in pharmaceutical distribution and healthcare services. Such items can show how McKesson supports access to therapies through its distribution networks and healthcare supply chain capabilities.
For readers tracking MCK news, this page provides a centralized view of financial announcements, strategic updates, capital allocation decisions, and partnership-related developments. Regularly reviewing these items can help investors and observers understand how McKesson communicates its performance, segment evolution, and strategic focus within the healthcare and wholesale trade landscape.
McKesson (NYSE: MCK) released its fiscal 2026 third quarter results and is hosting an earnings webcast today, Wednesday, February 4 at 4:30 PM ET. Investors can access the live audio webcast and archived materials, including the earnings release, financial tables, and slide presentation, on McKesson's Investor Relations website.
Additional investor events and presentations are listed at the company’s investor site.
McKesson (NYSE: MCK) has completed the sale of its retail and distribution businesses in Norway to NorgesGruppen, closing the transaction on January 30, 2026. This divestiture completes McKesson’s exit from its European operations and frees strategy and capital to prioritize growth in Oncology, Multispecialty and Biopharma Services.
Additional divestiture details will be discussed on the company’s Fiscal Third Quarter Earnings call on February 4, 2026 and posted on the investor relations website.
McKesson (NYSE: MCK) declared a quarterly cash dividend of $0.82 per share. The Board set the record date as March 2, 2026, and the payment date as April 1, 2026. This is a regular dividend payable to common shareholders.
McKesson (NYSE: MCK) will release third quarter fiscal 2026 results after market close on Wednesday, February 4, 2026. The company will host an investor earnings conference call and live webcast at 4:30 PM Eastern Time to review results. The live and archived audio webcast will be available on McKesson's Investor Relations website.
McKesson (NYSE: MCK) released its fiscal 2026 second quarter results and will host a live earnings conference call on Wednesday, November 5, 2025 at 4:30 PM ET.
Investors can access the live audio webcast, archived replay, earnings press release, financial tables, and slide presentation on McKesson's Investor Relations website at investor.mckesson.com.
Additional investor events and presentation schedules are listed at investor.mckesson.com/events-and-presentations.
McKesson (NYSE:MCK) announced a quarterly cash dividend of $0.82 per share. The Board declared the dividend on October 29, 2025; it is payable on January 2, 2026 to shareholders of record as of December 1, 2025.
Citius Oncology (Nasdaq: CTOR) signed a U.S. distribution services agreement with McKesson (NYSE: MCK) to serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl).
LYMPHIR is FDA approved for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. The McKesson agreement completes Citius Oncology's core U.S. distribution network with all three largest pharmaceutical wholesalers, supporting the planned commercial launch in Q4 2025. The company also cites inventory readiness, permanent J-code J9161, NCCN guideline inclusion, and provider and patient education resources as part of its commercialization preparations.
McKesson Corporation (NYSE: MCK) hosted its 2025 Investor Day, announcing significant strategic updates and improved financial outlook. The company raised its FY2026 Adjusted EPS guidance to $38.05-$38.55 from the previous $37.10-$37.90 range.
McKesson unveiled an updated organizational structure and new long-term growth targets, including an increased Adjusted EPS growth target of 13-16%, up from 12-14%. The company introduced segment-specific growth targets: North American Pharmaceutical (5-8%), Oncology & Multispecialty (13-16%), and Prescription Technology Solutions (10-13%).
The company is advancing its portfolio optimization, including the Medical-Surgical separation, while strengthening its position in oncology, multispecialty, and biopharma services platforms.
McKesson (NYSE: MCK) announced a strategic reorganization of its reportable segments, effective Q2 FY2026. The company will restructure into four main segments: North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.
The reorganization aims to enhance strategic focus on high-margin areas including oncology, multispecialty, and biopharma services. Notably, McKesson plans to separate its Medical-Surgical Solutions segment into an independent company, as announced in May 2025. Additionally, the company has entered into an agreement to sell its Norwegian operations, subject to regulatory approvals.
The company will provide additional details during its upcoming Investor Day on September 23, 2025.
McKesson Corporation (NYSE: MCK) has announced the release of its fiscal 2026 first quarter financial results. The company will host a live earnings conference call for investors on August 6, 2025, at 4:30 PM ET to discuss the quarterly performance.
Investors can access the financial results, earnings press release, financial tables, and slide presentation on McKesson's Investor Relations website. The audio webcast of the conference call will be available both live and archived at investor.mckesson.com/financials/quarterly-results.